1-15 of 15
Hedy L. Kindler
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors

Available to Purchase
Corey C. Foster, Gini F. Fleming, Theodore G. Karrison, Chih-Yi Liao, Ami V. Desai, John W. Moroney, Mark J. Ratain, Rita Nanda, Blase N. Polite, Olwen M. Hahn, Peter H. O'Donnell, Everett E. Vokes, Hedy L. Kindler, Robyn Hseu, Linda A. Janisch, Julia Dai, Mark D. Hoffman, Ralph R. Weichselbaum, Sean P. Pitroda, Steven J. Chmura, Jason J. Luke
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (20): 5510–5518.
https://doi.org/10.1158/1078-0432.CCR-21-0810
Published: 15 October 2021
View articletitled, Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors
Open the PDF for Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

5-FU, Irinotecan, Nab-Paclitaxel in Gastrointestinal Cancers—Response

Available to Purchase
Manish R. Sharma, Smita S. Joshi, Hedy L. Kindler
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (14): 3890.
https://doi.org/10.1158/1078-0432.CCR-20-1219
Published: 15 July 2020
View articletitled, 5-FU, Irinotecan, Nab-Paclitaxel in Gastrointestinal Cancers—Response
Open the PDF for 5-FU, Irinotecan, Nab-Paclitaxel in Gastrointestinal Cancers—Response in another window
Journal Articles

Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using UGT1A1 Genotype–Guided Dosing

Available to Purchase
Smita S. Joshi, Daniel V.T. Catenacci, Theodore G. Karrison, Jaclyn D. Peterson, Mark M. Zalupski, Amikar Sehdev, James Wade, Ahad Sadiq, Vincent J. Picozzi, Andrea Amico, Robert Marsh, Mark F. Kozloff, Blase N. Polite, Hedy L. Kindler, Manish R. Sharma
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (1): 18–24.
https://doi.org/10.1158/1078-0432.CCR-19-1483
Published: 03 January 2020
View articletitled, Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using UGT1A1 Genotype–Guided Dosing
Open the PDF for Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using UGT1A1 Genotype–Guided Dosing in another window
Includes: Supplementary data
Journal Articles

Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors

Free
Saoirse O. Dolly, Andrew J. Wagner, Johanna C. Bendell, Hedy L. Kindler, Lee M. Krug, Tanguy Y. Seiwert, Marjorie G. Zauderer, Martijn P. Lolkema, Doris Apt, Ru-Fang Yeh, Jill O. Fredrickson, Jill M. Spoerke, Hartmut Koeppen, Joseph A. Ware, Jennifer O. Lauchle, Howard A. Burris, 3rd, Johann S. de Bono
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (12): 2874–2884.
https://doi.org/10.1158/1078-0432.CCR-15-2225
Published: 14 June 2016
View articletitled, Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors
Open the PDF for Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Phase II Clinical Trial of Amatuximab, a Chimeric Antimesothelin Antibody with Pemetrexed and Cisplatin in Advanced Unresectable Pleural Mesothelioma

Free
Raffit Hassan, Hedy L. Kindler, Thierry Jahan, Lyudmila Bazhenova, Martin Reck, Anish Thomas, Ira Pastan, Jeff Parno, Daniel J. O'Shannessy, Penny Fatato, Julia D. Maltzman, Bruce A. Wallin
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (23): 5927–5936.
https://doi.org/10.1158/1078-0432.CCR-14-0804
Published: 30 November 2014
View articletitled, Phase II Clinical Trial of Amatuximab, a Chimeric Antimesothelin Antibody with Pemetrexed and Cisplatin in Advanced Unresectable Pleural Mesothelioma
Open the PDF for Phase II Clinical Trial of Amatuximab, a Chimeric Antimesothelin Antibody with Pemetrexed and Cisplatin in Advanced Unresectable Pleural Mesothelioma in another window
Includes: Supplementary data
Journal Articles

Prognostic and Predictive Blood-Based Biomarkers in Patients with Advanced Pancreatic Cancer: Results from CALGB80303 (Alliance)

Free
Andrew B. Nixon, Herbert Pang, Mark D. Starr, Paula N. Friedman, Monica M. Bertagnolli, Hedy L. Kindler, Richard M. Goldberg, Alan P. Venook, Herbert I. Hurwitz, for the Alliance for Clinical Trials In Oncology
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (24): 6957–6966.
https://doi.org/10.1158/1078-0432.CCR-13-0926
Published: 16 December 2013
View articletitled, Prognostic and Predictive Blood-Based Biomarkers in Patients with Advanced Pancreatic Cancer: Results from CALGB80303 (Alliance)
Open the PDF for Prognostic and Predictive Blood-Based Biomarkers in Patients with Advanced Pancreatic Cancer: Results from CALGB80303 (Alliance) in another window
Journal Articles

Putative Predictive Biomarkers of Survival in Patients with Metastatic Pancreatic Adenocarcinoma Treated with Gemcitabine and Ganitumab, an IGF1R Inhibitor

Free
Ian McCaffery, Yanyan Tudor, Hongjie Deng, Rui Tang, Samuel Suzuki, Sunita Badola, Hedy L. Kindler, Charles S. Fuchs, Elwyn Loh, Scott D. Patterson, Li Chen, Jennifer L. Gansert
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (15): 4282–4289.
https://doi.org/10.1158/1078-0432.CCR-12-1840
Published: 31 July 2013
View articletitled, Putative Predictive Biomarkers of Survival in Patients with Metastatic Pancreatic Adenocarcinoma Treated with Gemcitabine and Ganitumab, an IGF1R Inhibitor
Open the PDF for Putative Predictive Biomarkers of Survival in Patients with Metastatic Pancreatic Adenocarcinoma Treated with Gemcitabine and Ganitumab, an IGF1R Inhibitor in another window
Includes: Supplementary data
Journal Articles

A Genome-Wide Association Study of Overall Survival in Pancreatic Cancer Patients Treated with Gemcitabine in CALGB 80303

Free
Federico Innocenti, Kouros Owzar, Nancy L. Cox, Patrick Evans, Michiaki Kubo, Hitoshi Zembutsu, Chen Jiang, Donna Hollis, Taisei Mushiroda, Liang Li, Paula Friedman, Liewei Wang, Dylan Glubb, Herbert Hurwitz, Kathleen M. Giacomini, Howard L. McLeod, Richard M. Goldberg, Richard L. Schilsky, Hedy L. Kindler, Yusuke Nakamura, Mark J. Ratain
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (2): 577–584.
https://doi.org/10.1158/1078-0432.CCR-11-1387
Published: 16 January 2012
View articletitled, A Genome-Wide Association Study of Overall Survival in Pancreatic Cancer Patients Treated with Gemcitabine in CALGB 80303
Open the PDF for A Genome-Wide Association Study of Overall Survival in Pancreatic Cancer Patients Treated with Gemcitabine in CALGB 80303 in another window
Includes: Supplementary data
Journal Articles

The Cancer and Leukemia Group B Respiratory Committee

Free
Everett E. Vokes, Michael C. Perry, Hedy L. Kindler, Mark R. Green
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (11): 3581s–3588s.
https://doi.org/10.1158/1078-0432.CCR-06-9015
Published: 01 June 2006
View articletitled, The Cancer and Leukemia Group B Respiratory Committee
Open the PDF for The Cancer and Leukemia Group B Respiratory Committee in another window
Journal Articles

Gefitinib in Patients with Malignant Mesothelioma: A Phase II Study by the Cancer and Leukemia Group B

Free
Ramaswamy Govindan, Robert A. Kratzke, James E. Herndon, II, Gloria A. Niehans, Robin Vollmer, Dorothy Watson, Mark R. Green, Hedy L. Kindler, on behalf of the Cancer and Leukemia Group B (CALGB 30101)
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (6): 2300–2304.
https://doi.org/10.1158/1078-0432.CCR-04-1940
Published: 23 March 2005
View articletitled, Gefitinib in Patients with Malignant Mesothelioma: A Phase II Study by the Cancer and Leukemia Group B
Open the PDF for Gefitinib in Patients with Malignant Mesothelioma: A Phase II Study by the Cancer and Leukemia Group B in another window
Journal Articles

Delivery of a Liposomal c-raf-1 Antisense Oligonucleotide by Weekly Bolus Dosing in Patients with Advanced Solid Tumors: A Phase I Study

Free
Charles M. Rudin, John L. Marshall, Chao Hui Huang, Hedy L. Kindler, Chuanbo Zhang, Deepak Kumar, Prafulla C. Gokhale, Joyce Steinberg, Steve Wanaski, Usha N. Kasid, Mark J. Ratain
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (21): 7244–7251.
https://doi.org/10.1158/1078-0432.CCR-04-0642
Published: 08 November 2004
View articletitled, Delivery of a Liposomal c-raf-1 Antisense Oligonucleotide by Weekly Bolus Dosing in Patients with Advanced Solid Tumors: A Phase I Study
Open the PDF for Delivery of a Liposomal c-raf-1 Antisense Oligonucleotide by Weekly Bolus Dosing in Patients with Advanced Solid Tumors: A Phase I Study in another window
Journal Articles

Phase II Study of the Proteasome Inhibitor Bortezomib (PS-341) in Patients with Metastatic Neuroendocrine Tumors

Free
Manisha H. Shah, Donn Young, Hedy L. Kindler, Iain Webb, Barbara Kleiber, John Wright, Michael Grever
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (18): 6111–6118.
https://doi.org/10.1158/1078-0432.CCR-04-0422
Published: 24 September 2004
View articletitled, Phase II Study of the Proteasome Inhibitor Bortezomib (PS-341) in Patients with Metastatic Neuroendocrine Tumors
Open the PDF for Phase II Study of the Proteasome Inhibitor Bortezomib (PS-341) in Patients with Metastatic Neuroendocrine Tumors in another window
Journal Articles

Dose-Ranging Study of the Safety and Pharmacokinetics of Atrasentan in Patients with Refractory Malignancies

Free
Christopher W. Ryan, Nicholas J. Vogelzang, Everett E. Vokes, Hedy L. Kindler, Samir D. Undevia, Rod Humerickhouse, Amy K. André, Qiang Wang, Robert A. Carr, Mark J. Ratain
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (13): 4406–4411.
https://doi.org/10.1158/1078-0432.CCR-04-0083
Published: 06 July 2004
View articletitled, Dose-Ranging Study of the Safety and Pharmacokinetics of Atrasentan in Patients with Refractory Malignancies
Open the PDF for Dose-Ranging Study of the Safety and Pharmacokinetics of Atrasentan in Patients with Refractory Malignancies in another window
Journal Articles

A Phase I Study of Cantuzumab Mertansine Administered as a Single Intravenous Infusion Once Weekly in Patients with Advanced Solid Tumors

Free
Paul R. Helft, Richard L. Schilsky, Frank J. Hoke, Daphne Williams, Hedy L. Kindler, Evie Sprague, Mark DeWitte, Helen K. Martino, John Erickson, Lini Pandite, Mark Russo, John M. Lambert, Maria Howard, Mark J. Ratain
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (13): 4363–4368.
https://doi.org/10.1158/1078-0432.CCR-04-0088
Published: 06 July 2004
View articletitled, A Phase I Study of Cantuzumab Mertansine Administered as a Single Intravenous Infusion Once Weekly in Patients with Advanced Solid Tumors
Open the PDF for A Phase I Study of Cantuzumab Mertansine Administered as a Single Intravenous Infusion Once Weekly in Patients with Advanced Solid Tumors in another window
Journal Articles

Phase I Clinical and Pharmacokinetic Study of Protein Kinase C-α Antisense Oligonucleotide ISIS 3521 Administered in Combination with 5-Fluorouracil and Leucovorin in Patients with Advanced Cancer

Free
Sridhar Mani, Charles M. Rudin, Katie Kunkel, Jon T. Holmlund, Richard S. Geary, Hedy L. Kindler, F. Andrew Dorr, Mark J. Ratain
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (4): 1042–1048.
Published: 01 April 2002
View articletitled, Phase I Clinical and Pharmacokinetic Study of Protein Kinase C-α Antisense Oligonucleotide ISIS 3521 Administered in Combination with 5-Fluorouracil and Leucovorin in Patients with Advanced Cancer
Open the PDF for Phase I Clinical and Pharmacokinetic Study of Protein Kinase C-α Antisense Oligonucleotide ISIS 3521 Administered in Combination with 5-Fluorouracil and Leucovorin in Patients with Advanced Cancer in another window